公开(公告)号：US08809265B2

公开(公告)日：2014-08-19

申请号：US13656012

申请日：2012-10-19

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC: A01N37/18 ,  A61K38/00 ,  A61P1/16 ,  A01N43/04 ,  A61K31/70 ,  A61K31/4709 ,  A61K31/7072 ,  A61K31/4725 ,  A61K31/4025 ,  A61K31/501 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/513 ,  A61K31/4178 ,  A61K31/473 ,  A61K31/4196

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/473 ,  A61K31/501 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/7072 ,  A61K38/05 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Abstract translation: 本发明的特征在于用于治疗HCV的干扰素和不含利巴韦林的疗法。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 在一个方面，所述疗法包括向具有HCV感染的受试者施用至少两种没有干扰素和利巴韦林的直接作用的抗病毒剂。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2（或治疗剂3）和细胞色素P450（例如利托那韦）的抑制剂。

公开(公告)号：US20240232171A1

公开(公告)日：2024-07-11

申请号：US18613308

申请日：2024-03-22

Applicant: ABBVIE INC.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: G06F16/23 ,  G06F7/00 ,  G06F16/215 ,  G06F16/25

CPC classification number: G06F16/2365 ,  G06F7/00 ,  G06F16/215 ,  G06F16/2379 ,  G06F16/252

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11285159B2

公开(公告)日：2022-03-29

申请号：US17089415

申请日：2020-11-04

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： John Hayslip ,  Leanne M. Holes ,  Sven Mensing ,  Silpa Nuthalapati

IPC: A61K31/5377 ,  A61K31/52 ,  A61P35/00

Abstract: The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.

公开(公告)号：US20180177779A1

公开(公告)日：2018-06-28

申请号：US15738773

申请日：2016-07-07

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K31/498 ,  A61K31/454 ,  A61K31/7072 ,  A61P31/14

CPC classification number: A61K31/498 ,  A61K31/454 ,  A61K31/7056 ,  A61K31/7072 ,  A61P31/14 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20180042982A1

公开(公告)日：2018-02-15

申请号：US15782162

申请日：2017-10-12

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Tami Pilot-Matias ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Lino Rodrigues Junior ,  Suvajit Samanti ,  Roger Trinh ,  Tianli Wang ,  Betty B. Yao

IPC: A61K38/06 ,  A61K31/7072 ,  A61K31/4184 ,  A61K31/7056

CPC classification number: A61K38/06 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K2300/00

Abstract: The present invention generally features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16, 12 or 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. Further, additional compounds such as sofosbuvir, or its pharmaceutically acceptable salt may be used for retreatment of HCV patients who have failed glecaprevir and pibrentasvir combination therapy.

公开(公告)号：US20170151238A1

公开(公告)日：2017-06-01

申请号：US15431906

申请日：2017-02-14

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K31/498 ,  A61K31/454

CPC classification number: A61K31/498 ,  A61K31/454 ,  A61K38/05 ,  A61K38/06 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US08853176B2

公开(公告)日：2014-10-07

申请号：US13656024

申请日：2012-10-19

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC: A01N43/04 ,  A61K31/70 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/4178 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/4709 ,  A61K31/4025

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/439 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/06 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

公开(公告)号：US20130102557A1

公开(公告)日：2013-04-25

申请号：US13656024

申请日：2012-10-19

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC: A61K31/7056 ,  A61P31/14

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/439 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/06 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

公开(公告)号：US20240115650A1

公开(公告)日：2024-04-11

申请号：US18534967

申请日：2023-12-11

Applicant: ABBVIE INC.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05

CPC classification number: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220288153A1

公开(公告)日：2022-09-15

申请号：US17484287

申请日：2021-09-24

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.